Transcranial alternating current stimulation (tACS) may enhance cognition and potentiate digital cognitive training (DCT) in mild cognitive impairment (MCI). Optimal intensity remains uncertain because higher currents may increase cortical electric fields but raise tolerability concerns. We evaluated feasibility and tolerability of 3.2 mA tACS plus DCT, and exploratorily assessed active versus sham effects on inhibitory control and cognitive transfer. Ten older adults with MCI received five daily 6-Hz tACS sessions over the left dorsolateral prefrontal cortex during DCT; ten sham-arm participants from a randomized trial completed identical DCT. Feasibility and tolerability were assessed by adherence, attrition, and side-effect monitoring. Exploratory efficacy used repeated-measures ANOVA with Bonferroni-corrected paired comparisons. Outcomes included antisaccade total errors, verbal and visual memory, and visuoconstructive abilities. All participants completed treatment (100
Rimegepant and lasmiditan are effective acute migraine treatments, but real-world head-to-head comparative data are lacking. We aimed to compare their effectiveness and tolerability in clinical practice. This post-hoc study indirectly compared two prospective, multicenter, real-world studies (GAINER and DART). Participants treated up to four migraine attacks with rimegepant 75 mg orally disintegrating tablets or lasmiditan 50 or 100 mg. Data were collected using an electronic diary every 30 min up to 2 hours after dosing. The co-primary outcomes were 2-hour pain freedom and incidence of adverse events (AEs) comparing rimegepant with lasmiditan in the first treated attack. The overall cohort included 249 individuals, 58 treated with lasmiditan and 191 with rimegepant (81.1 www.clinicaltrial.gov : NCT05903027; DART registration at www.clinicaltrial.gov : NCT05903040.
Anxiety and depression are highly prevalent non-motor symptoms in Parkinson's disease (PD), severely compromising health-related quality of life. Conventional pharmacological management is frequently constrained by adverse effects, polypharmacy, and pharmacokinetic interactions. Cognitive Behavioral Therapy (CBT) represents a promising structured non-pharmacological strategy, but an updated, comprehensive synthesis of clinical trial evidence is warranted. To systematically evaluate the efficacy and clinical safety profile of CBT for alleviating anxiety and depressive symptoms in patients with PD. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted in accordance with the PRISMA 2020 guidelines. PubMed, Embase, the Cochrane Library, and Web of Science were searched from database inception to October 2025. RCTs evaluating CBT (≥ 4 sessions over ≥ 4 weeks) versus control conditions (e.g., treatment as usual, waitlist, active controls) in adults with PD reporting anxiety and/or depression outcomes were included. Two reviewers independently screened literature, extracted data, and assessed methodological quality using the Cochrane Risk of Bias tool. Standardized mean differences (SMDs) with 95
Hereditary transthyretin amyloidosis (ATTRv) is a rare, progressive multisystem disorder caused by pathogenic variants in the TTR gene. This study aimed to describe the distribution of TTR pathogenic variants and associated clinical phenotypes across Italy using data from a large national genetic testing cohort. This retrospective study analyzed genetic and clinical data from individuals referred for TTR gene sequencing at a single reference laboratory between June 2016 and December 2023. Coding exons 2–4 and exon–intron boundaries of the TTR gene were sequenced by the Sanger method. Variants were classified according to ACMG/AMP criteria. Descriptive analyses summarized variant frequencies, regional distributions, and genotype–phenotype correlations. One hundred ninety-five individuals were included, comprising 94 affected patients and 101 asymptomatic carriers. Mean age was 56.8 years, 57.9
